AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19963403
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (ARTZ Dispo) 25 mg/wk for 5 weeks
Trial: 16905181
Drug: High-risk cardiovascular
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk cardiovascular prevention approach including complete registration of risk factors, optimization of medical treatment, and health counseling on high fat consumption, smoking, and physical inactivity.
Trial: 8460758
Drug: Morphine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine at 1 mg.h-1 combined with ketamine at 5 mg.h-1
Trial: 8460758
Drug: Morphine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine at 1 mg.h-1 combined with ketamine at 10 mg.h-1
Trial: 8460758
Drug: Morphine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine at 1 mg.h-1 combined with ketamine at 20 mg.h-1
Trial: 8460758
Drug: Morphine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine at 1 mg.h-1 alone
Trial: 31902378
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids from flaxseed oil (2 × 1000 mg/d, containing 400 mg α-linolenic acid per capsule)
Trial: 27825572
Drug: Ice (30min,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice (30min, applied twice at 8h interval)
Trial: 27825572
Drug: Cold CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold CO2 (2min, applied twice at 8h interval)
Trial: 26000667
Drug: 8 mL
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL of 0.5% lidocaine (group L)
Trial: 26000667
Drug: 6 mL
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL of 0.5% lidocaine mixed with 80 mg (2 mL) of methylprednisolone acetate (group LS)
Trial: 26000667
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L and LS)
Trial: 23433200
Drug: Probiotic compound
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic compound (seven bacterial species including Lactobacillus and Bifidobacterium strains and Streptococcus thermophiles)
Trial: 23433200
Drug: Probiotic compound
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic compound
Trial: 23433200
Drug: Probiotic compound
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic compound and Placebo
Trial: 21840828
Drug: Highly Purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly Purified Follicle Stimulating Hormone (HP-FSH)
Trial: 21840828
Drug: Recombinant Follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Follicle Stimulating Hormone (rFSH)
Trial: 10095928
Drug: Escherichia coli
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escherichia coli resistant to antibiotics
Trial: 10095928
Drug: Escherichia coli
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escherichia coli resistant to various antibiotics
Trial: 10095928
Drug: Escherichia coli
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escherichia coli resistant to five or more antibiotics
Trial: 14621746
Drug: PGE1 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (40 microg/kg twice a day, intravenously from day 1 to day 7)
Trial: 414280
Drug: L-Dopa (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa (1.5 g)
Trial: 414280
Drug: Aminophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (200 mg)
Trial: 414280
Drug: Aminophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (200 mg) plus Ephedrine (50 mg)
Trial: 28679605
Drug: Direct NIV
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct NIV discontinuation (n=59)
Trial: 26118825
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg every-other-week
Trial: 26118825
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg every-other-week
Trial: 26118825
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation to 80 mg every-other-week for patients with suboptimal response to 40 mg
Trial: 26118825
Drug: Adalimumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (both doses)
Trial: 21717822
Drug: Policosanol 20
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 20 mg/day for 12 weeks
Trial: 11166969
Drug: MST (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST (oral retarded morphine sulphate)
Trial: 9731991
Drug: Lansoprazole in
RxNorm normalized name: lansoprazole Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole in combination with antibiotics (amoxicillin, clarithromycin, metronidazole, or tinidazole)
Trial: 9731991
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy including lansoprazole
Trial: 9731991
Drug: Lansoprazole vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole vs. other PPIs (e.g., omeprazole)
Trial: 7987362
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (4 g/day for 14 days)
Trial: 7987362
Drug: L-carnitine (L-CN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (L-CN, Day 28)
Trial: 31633844
Drug: Ampicillin-sulbactam plus
RxNorm normalized name: ampicillin / sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam plus amoxicillin-clavulanic acid
Trial: 31633844
Drug: Erythromycin plus
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin plus ampicillin plus amoxicillin
Trial: 23782590
Drug: TAU +
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU + SWT (Treatment As Usual + Structured Writing Therapy)
Trial: 23782590
Drug: TAU (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (Treatment As Usual)
Trial: 20479668
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin 900 mg plus normal saline infiltration (G)
Trial: 20479668
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin 900 mg plus 2% lidocaine infiltration (GL)
Trial: 20479668
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo plus 2% lidocaine infiltration (L)
Trial: 20479668
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin 900 mg (G)
Trial: 14656787
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask at 5 L*min(‐1)
Trial: 14656787
Drug: Mike Cannula
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mike Cannula at 5 L*min(‐1)
Trial: 11448573
Drug: CR (20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR (20.0 g of CR/d for 7 d followed by 10.0 g of CR/d for 14 d)
Trial: 11448573
Drug: HMB (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB (3.0 g of HMB/d)
Trial: 7804510
Drug: Urapidil (U)
DrugBank: Urapidil (DB12661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (U) - bolus of 25 mg; initial infusion rate of 15-85 micrograms/kg/min; maintenance infusion rate of 2-7 micrograms/kg/min
Trial: 7804510
Drug: Sodium Nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium Nitroprusside (S) - initial infusion rate of 1-2 micrograms/kg/min; maintenance infusion rate of max. 5 micrograms/kg/min
Trial: 30189012
Drug: Oxycodone/naloxone (5/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/naloxone (5/2.5 or 10/5 mg) during haemodialysis
Trial: 30189012
Drug: Oxycodone/naloxone (5/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/naloxone (5/2.5 or 10/5 mg) between haemodialysis sessions
Trial: 27973690
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading after implant placement (N = 81, group A)
Trial: 22639013
Drug: 1.8 g
RxNorm normalized name: Calciquid, 1.8 g/5 mL oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g of sodium
Trial: 22639013
Drug: 3.8 g
RxNorm normalized name: dextrin 3 gram/3.8 gram ORAL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.8 g of sodium
Trial: 22639013
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake <4.5 g/day
Trial: 22639013
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake >4.5 g/day
Trial: 19224430
Drug: PIO (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIO (45 mg) + placebo
Trial: 19224430
Drug: SIMVA (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIMVA (40 mg) + placebo
Trial: 19224430
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (PIO, SIMVA, PIO + SIMVA)
Trial: 17568648
Drug: Transient VEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transient VEP in response to isoluminant chromatic (L-M) sinewave gratings
Trial: 7614520
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg (titrated up to 40 mg) once in the evening
Trial: 25608587
Drug: Isoniazid treatment
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid treatment
Trial: 28332191
Drug: Combined Er:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Er:YAG (160 mJ/pulse, 10 Hz) and Nd:YAG laser (100 mJ/pulse, 20 Hz) therapy
Trial: 21444654
Drug: Robotic-assisted gait
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-assisted gait training (20 sessions in the first 4 weeks of inpatient therapy)
Trial: 17542202
Drug: Fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride toothpaste (Elmex sensitive toothpaste, 1400 ppm F) plus fluoride mouthrinse (Elmex sensitive rinse containing 250 ppm F) used twice a day.
Trial: 17542202
Drug: Placebo mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthrinse without fluoride used twice a day with the same fluoride toothpaste.
Trial: 15509203
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sublingual sildenafil
Trial: 11827307
Drug: ELISA alone
RxNorm normalized name: pseudopterogorgia elisabethae extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELISA alone or in combination with SPT
Trial: 9290020
Drug: Sex hormone
RxNorm normalized name: Sex hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone receptors
Trial: 1764956
Drug: Fendiline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendiline (75 mg twice daily)
Trial: 6805031
Drug: Ethanol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.75 g/kg) + Naloxone (0.4 mg)
Trial: 6805031
Drug: Ethanol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.75 g/kg) + Saline
Trial: 30943275
Drug: Azilsartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan (20 mg/day)
Trial: 23942133
Drug: Oral etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral etoricoxib
Trial: 25262192
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin
Trial: 12773446
Drug: Follitropin beta
RxNorm normalized name: Follitropin Beta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin beta administered by a pen device
Trial: 12773446
Drug: Follitropin alpha
RxNorm normalized name: follitropin alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin alpha administered by a conventional syringe
Trial: 1492932
Drug: Eflornithine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine (400 mg/kg daily, continuous intravenous infusion)
Trial: 1492932
Drug: Cotrimoxazole (3.84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (3.84 g twice daily, intravenously)
Trial: 1492932
Drug: Eflornithine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine (400 mg/kg daily)
Trial: 1492932
Drug: Cotrimoxazole (7.68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (7.68 g daily)
Trial: 26936480
Drug: Youth mentor-led
RxNorm normalized name: Mentol
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Youth mentor-led nutritional intervention (BHCK); bi-weekly interactive sessions delivered by 16 youth leaders.
Trial: 19249751
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine self-administration (1.0 mg/kg)
Trial: 8098220
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of bisoprolol daily for two weeks
Trial: 3101553
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate eye ointment
Trial: 31568587
Drug: Low-dose exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exercise (150 minutes per week)
Trial: 31568587
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise (300 minutes per week)
Trial: 28551073
Drug: Ixekizumab every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab every 4 weeks (80 mg after a 160 mg starting dose)
Trial: 28551073
Drug: Ixekizumab every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab every 2 weeks (80 mg after a 160 mg starting dose)
Trial: 22846777
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg liraglutide
Trial: 27282158
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg liraglutide
Trial: 27282158
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg liraglutide
Trial: 21905751
Drug: Mixed nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed nuts consumption (30 g/day)
Trial: 9393746
Drug: Nicotinamide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (80 mg/kg)
Trial: 24005608
Drug: Mekabu fucoidan
RxNorm normalized name: Fucidin
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mekabu fucoidan (MF) 300 mg/d
Trial: 15298073
Drug: NCX-701 (nitric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX-701 (nitric oxide-releasing derivative of paracetamol)
Trial: 11703886
Drug: Serotonin agents
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin agents
Trial: 8990428
Drug: Partially home-based
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially home-based moderate-intensity aerobic exercise program (30 minutes, 3-4 times weekly at 70% of estimated maximal heart rate)
Trial: 8491069
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg ibuprofen and 15 mg/kg acetaminophen
Trial: 24368060
Drug: early modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: early modified IPS intervention in addition to treatment-as-usual
Trial: 24368060
Drug: treatment-as-usual alone
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual alone
Trial: 17967917
Drug: DHA-PQ (piperaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-PQ (piperaquine phosphate at 20 mg/kg/day for 3 days)
Trial: 17967917
Drug: CQ-SP (chloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQ-SP (chloroquine at 10 mg base/kg/day for 3 days with a single dose of sulfadoxine-pyrimethamine)
Trial: 14655921
Drug: Novel Bilevel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel Bilevel (NBL) therapy
Trial: 10394523
Drug: Ultrashort stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrashort stimulation (gonadotropin releasing hormone agonist plus hMG or FSH)
Trial: 6429406
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with EAA (2.3 g of nitrogen per day)
Trial: 6429406
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with ENAA (11.3 g of nitrogen per day)
Trial: 26833396
Drug: VR exposure
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR exposure therapy (n = 50)
Trial: 18046926
Drug: Prandial premixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prandial premixed insulin analogues (70% or 75% basal and 30% or 25% rapid-acting insulin analogue)
Trial: 18046926
Drug: Prandial premixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prandial premixed insulin analogues (50% basal and 50% rapid-acting insulin analogue)
Trial: 18046926
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin analogues
Trial: 11921591
Drug: Paracetamol (washout
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (washout period)
Trial: 3047900
Drug: Mucoregulatory agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucoregulatory agents
Trial: 28355362
Drug: 10% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydrogen peroxide (Oral B 3D White - Oral-B)
Trial: 23698019
Drug: 1 injection
RxNorm normalized name: vitamin K1 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of lidocaine (0.5%)
Trial: 23698019
Drug: 5 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 injections of lidocaine (0.5%)
Trial: 23698019
Drug: 1 injection
RxNorm normalized name: vitamin K1 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection of saline (NaCl 0.9%)
Trial: 23698019
Drug: 5 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 injections of saline (NaCl 0.9%)
Trial: 20518813
Drug: Effervescent tablets
RxNorm normalized name: Hydralyte Effervescent Tablets Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablets and ultrasonic device
Trial: 18348774
Drug: Tinidazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (single dose of 50 mg/kg)
Trial: 18348774
Drug: Nitazoxanide (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (7.5 mg/kg twice a day for 3 days)
Trial: 11954681
Drug: All interventions
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All interventions including the most important and adjunctive ones
Trial: 7650235
Drug: Butorphanol nasal
RxNorm normalized name: butorphanol nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol nasal spray (1 mg)
Trial: 7650235
Drug: Butorphanol nasal
RxNorm normalized name: butorphanol nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol nasal spray plus sumatriptan (1 mg butorphanol + 6 mg SC sumatriptan)
Trial: 7650235
Drug: Butorphanol nasal
RxNorm normalized name: butorphanol nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol nasal spray
Trial: 410176
Drug: no additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no additional therapy
Trial: 30776911
Drug: Psychiatric health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric health and substance use issues (depression, anxiety, drug use)
Trial: 28668399
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity statin therapy (atorvastatin 80mg/day)
Trial: 28668399
Drug: Moderate intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate intensity statin therapy (atorvastatin 20mg/day)
Trial: 21665007
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of sertraline plus 2 g/day omega‐3 fatty acids
Trial: 21665007
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of sertraline plus 2 g/day corn oil placebo capsules
Trial: 8422085
Drug: l-deprenyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-deprenyl (5 mg b.i.d.)